Dimensional Fund Advisors
LXEO icon

Dimensional Fund Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Dimensional Fund Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.99M Buy
1,287,185
+183,601
+17% +$993K ﹤0.01% 2490
2026
Q1 		$6.33M Buy
1,103,584
+240,692
+28% +$1.71M ﹤0.01% 2421
2025
Q4 		$8.57M Sell
862,892
-49,641
-5% -$453K ﹤0.01% 2339
2025
Q3 		$6.06M Buy
912,533
+865,510
+1,841% +$4.19M ﹤0.01% 2485
2025
Q2 		$189K Buy
+47,023
New +$155K ﹤0.01% 3122

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Dimensional Fund Advisors's LXEO Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Lexeo Therapeutics (LXEO) stake by 17% in Q2 2026, buying an estimated $993K and bringing the position to 1,287,185 shares worth $5.99M. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Dimensional Fund Advisors first reported a position in LXEO in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.57M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Dimensional Fund Advisors held 1,287,185 shares of Lexeo Therapeutics worth $5.99M as of Q2 2026.
  • Dimensional Fund Advisors bought 183,601 Lexeo Therapeutics shares in Q2 2026, an estimated $993K.
  • Lexeo Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2490 holding.
  • Dimensional Fund Advisors first reported a position in Lexeo Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Dimensional Fund Advisors's Lexeo Therapeutics position peaked at $8.57M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.